iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function

Matthew A. Brooke, Sarah L. Etheridge, Nihal Kaplan, Charlotte Simpson, Edel A. O'Toole, Akemi Ishida-Yamamoto, Olivier Marches, Spiro Getsios, David P. Kelsell*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


iRHOM2 is a highly conserved, catalytically inactive member of the Rhomboid family, which has recently been shown to regulate the maturation of the multi-substrate ectodomain sheddase enzyme ADAM17 (TACE) in macrophages. Dominant iRHOM2 mutations are the cause of the inherited cutaneous and oesophageal cancer-susceptibility syndrome tylosis with oesophageal cancer (TOC), suggesting a role for this protein in epithelial cells. Here, using tissues derived from TOC patients, we demonstrate that TOC-associated mutations in iRHOM2 cause an increase in the maturation and activity of ADAM17 in epidermal keratinocytes, resulting in significantly upregulated shedding of ADAM17 substrates, including EGF-family growth factors and proinflammatory cytokines. This activity is accompanied by increased EGFR activity, increased desmosome processing and the presence of immature epidermal desmosomes, upregulated epidermal transglutaminase activity and heightened resistance to Staphylococcal infection in TOC keratinocytes. Many of these features are consistent with the presence of a constitutive wound-healing-like phenotype in TOC epidermis, which may shed light on a novel pathway in skin repair, regeneration and inflammation.

Original languageEnglish (US)
Article numberddu120
Pages (from-to)4064-4076
Number of pages13
JournalHuman molecular genetics
Issue number15
StatePublished - Aug 2014

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics
  • Molecular Biology


Dive into the research topics of 'iRHOM2-dependent regulation of ADAM17 in cutaneous disease and epidermal barrier function'. Together they form a unique fingerprint.

Cite this